BioVaxy Announces Findings For Use of DPX in Vaccine Development

Stock.adobe.com

BioVaxys Technology Corp announced key findings from its research into the use of novel lipid-in-oil delivery platform (DPX) to deliver a variety of molecules.¹ According to the research, the platform was able to produce targeted immune responses for multiple disease states.

In a press release, BioVaxy’s president and chief operating officer Kenneth Kovan said, “With data so compelling and supportive of the value of DPX-based vaccines for infectious diseases, we are seeking various off-balance sheet avenues to support development.The significant cargo capacity of DPX and the proven ability to package diverse antigens such as that shown with our DPX-SurMAGE multi-antigen cancer vaccine, could also greatly benefit potential partnerships for developing more effective viral vaccines, such as a multivalent mRNA DTP vaccine to address the recognized problem of immunity to the Bordetella pertussis waning over time, or for emerging global diseases such as MPox, where a DPX-mRNA formulation could have significant advantage. This fits well with our strategy of expanding development partnerships with DPX beyond oncology."

In July, BioVaxys announced that it had executed a binding letter of intent to use DPX to develop vaccines for life threatening food allergies.²

At the time, Kovan said, “Our ability to tackle this unmet medical need is directly attributable to the immune educating capability and highly flexible antigen loading capacity of our DPX™ platform. With the DPX™ platform already the backbone of multiple BioVaxys clinical programs in oncology and infectious disease, we see a staggering opportunity for continued expansion into other novel DPX-formulations with polynucleotides, peptides, proteins, virus-like articles, and small molecules."

In the same press release, BioVaxy’s CEO James Passin said, “Competing approved allergy desensitization treatments require weekly treatments, have risk of anaphylaxis, and take years to compete–compliance with this therapy is very difficult for parents. Recently approved monoclonal antibody treatment carries a cost of US$ 2,900 and US$ 5,000 per month which could place treatment out of reach for sone patients. We look forward to completing preclinical studies with our development partners, and anticipate an emerging profile for a single dose, long duration, product consistent with other DPX formulations."

Earlier in July, BioVaxy announced that the US Patent and Trademark office had issued a patent for a DPX related product, a B-cell epitope that had been formulated on the platform.³ At the time, Kovan said, “Issuance of this Patent by the USPTO expands the value of our IP and DPX platform, and puts the Company on strong footing for further development and partnering with companies developing epitope-based vaccines for diseases such as chronic hepatitis-B, influenza, and RSV, where we have such promising human study results."

Also in July, BioVaxy announced that Brittany Davison, CPA, CA, had joined the company as a business advisor.⁴ According to Kovan, “We are delighted to have engaged Brittany who is a significant addition to our team where she will assist with further knowledge transfer associated with the former IMV, Inc. assets, support investor relations, business development targeting and outreach, and facilitate sources of private funding, government funding and Scientific Research and Experimental Development (SR&ED) tax incentives."

Sources

1. BioVaxys DPX-Based Vaccines Exhibit Robust Efficacy Across Multiple Infectious Diseases. BioVaxys Technology Corp. August 22, 2024. https://www.prnewswire.com/news-releases/biovaxys-dpx-based-vaccines-exhibit-robust-efficacy-across-multiple-infectious-diseases-302228589.html
2. Biovaxys Signs Binding Letter of Intent to Develop DPX™-Based Vaccines for Life Threatening Food Allergies. BioVaxys Technology Corp. July 29, 2024. Accessed August 23, 2024. https://www.prnewswire.com/news-releases/biovaxys-signs-binding-letter-of-intent-to-develop-dpx-based-vaccines-for-life-threatening-food-allergies-302208457.html
3. Biovaxys Announces Issuance of DPX Related Patent from the U.S. Patent and Trademark Office. BioVaxys Technology Corp. July 23, 2024. https://www.prnewswire.com/news-releases/biovaxys-announces-issuance-of-dpx-related-patent-from-the-us-patent-and-trademark-office-302203828.html
4. Brittany Davison, CPA, CA, Joins BioVaxys as Business Advisor. BioVaxys Technology Corp. July 18, 2024. Accessed August 23, 2024. https://www.prnewswire.com/news-releases/brittany-davison-cpa-ca-joins-biovaxys-as-business-advisor-302200520.html